Michels Ingo Ilja, Fang Yu-Xia, Zhao Dong, Zhao Li-Yan, Lu Lin
Office of the Federal Drug Commissioner, Federal Ministry of Health, Berlin 10117, Germany.
Acta Pharmacol Sin. 2007 Oct;28(10):1505-18. doi: 10.1111/j.1745-7254.2007.00633.x.
Drug abuse has a long, but also different history in Germany and China. The Opium War largely influenced the history of China in 19th century; however, China was once recognized as a drug-free nation for 3 decades from the 1950s to the 1980s. Drug abuse has spread quickly since re-emerging as a national problem in China in the late 1980s. The number of registered drug abusers increased from 70 000 in 1990 to more than 1 million by the end of 2005. In past decades, illicit drug trafficking and production have swept most provinces in China, and drug abuse has caused many problems for both abusers and the community. One major drug-related problem is the spread of HIV, which has caused major social and economic damage in China. Germany, the largest developed European country, also faces the drug and addiction problem. Germany has about 150 000 heroin addicts, for whom HIV/AIDS has become a serious threat since the mid 1980s. To control the drug problem, the German Government adopted the pAction Plan on Drugs and Addictionq in 2003; the China Central Government approved a similar regulation in the antidrug campaign in 2005. Germany has experience in reducing drug-related harm. The methadone maintenance treatment (MMT) program has run for more than 20 years and the public has become more tolerant of addicts. In 2003, China began the MMT program for controlling the spread of HIV/AIDS. It is necessary for China to learn from developed countries to acquire success in its antidrug campaign. In this review, we will go over the differences and similarities in drug abuse between Germany and China. The differences are related to history, population and economics, drug policy context, drug laws, HIV/hepatitis C virus infection, the MMT program and so on. These 2 nations have drug abuse problems with different histories and currently use different approaches to handle illicit drug marketing and use. The legal penalties for illicit drug offences reflect the social differences of these 2 nations with respect to the seriousness of particular types of crimes. The characteristics of the MMT program may also influence patterns of drug abuse in these 2 nations and China should improve the MMT program based on the successful model in Europe, the USA, and Australia. We recommend more dialogue and collaboration between Germany and China.
药物滥用在德国和中国有着漫长但又不尽相同的历史。鸦片战争在很大程度上影响了中国19世纪的历史;然而,从20世纪50年代到80年代,中国曾有30年被视为无毒品国家。自20世纪80年代末再次成为一个全国性问题以来,药物滥用在中国迅速蔓延。登记在册的吸毒者人数从1990年的7万增加到2005年底的100多万。在过去几十年里,非法毒品贩运和生产席卷了中国的大部分省份,药物滥用给吸毒者和社会都带来了许多问题。一个与毒品相关的主要问题是艾滋病毒的传播,这在中国造成了重大的社会和经济损害。德国作为欧洲最大的发达国家,也面临着毒品和成瘾问题。德国约有15万海洛因成瘾者,自20世纪80年代中期以来,艾滋病毒/艾滋病对他们构成了严重威胁。为了控制毒品问题,德国政府在2003年通过了《毒品和成瘾行动计划》;中国中央政府在2005年的禁毒运动中批准了一项类似的规定。德国在减少与毒品相关的危害方面有经验。美沙酮维持治疗(MMT)项目已经开展了20多年,公众对成瘾者也更加宽容。2003年,中国开始实施美沙酮维持治疗项目以控制艾滋病毒/艾滋病的传播。中国有必要向发达国家学习,以便在禁毒运动中取得成功。在这篇综述中,我们将探讨德国和中国在药物滥用方面的异同。这些差异涉及历史、人口和经济、毒品政策背景、毒品法律、艾滋病毒/丙型肝炎病毒感染、美沙酮维持治疗项目等。这两个国家有着不同历史的药物滥用问题,目前在处理非法毒品销售和使用方面采用不同的方法。对非法毒品犯罪的法律处罚反映了这两个国家在特定类型犯罪严重性方面的社会差异。美沙酮维持治疗项目的特点也可能影响这两个国家的药物滥用模式,中国应基于欧洲、美国和澳大利亚的成功模式改进美沙酮维持治疗项目。我们建议德国和中国之间开展更多对话与合作。